SCHEMBL2261644

SCHEMBL2261644

Cc1cc(C#N)cc(Cl)c1Oc1nc(NC2CCN(c3cccc(S(C)(=O)=O)c3)CC2)ncc1Br

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 6/20 0.43
CYP2C9 P11712 3/20 0.38
SMO Q99835 1/20 0.37
CCNT1 O60563 1/20 0.37
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CCNB1 P14635 1/20 0.37
CCND1 P24385 1/20 0.37
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
CCND3 P30281 1/20 0.37
CDK7 P50613 1/20 0.37
CDK9 P50750 1/20 0.37
CCNH P51946 1/20 0.37
MNAT1 P51948 1/20 0.37
CDK6 Q00534 1/20 0.37
NR1H2 P55055 6/20 0.36
NR1H3 Q13133 4/20 0.35
CCNK O75909 1/20 0.35
CDK12 Q9NYV4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2263668 0.95 KCNH2 (0.46) KCNH2CYP2C9CDK4NR1H2NR1H3
SCHEMBL2259866 0.90 KCNH2 (0.47) KCNH2CYP2C9SMOCCNT1CDK1
SCHEMBL2260716 0.89 KCNH2 (0.45) KCNH2CYP2C9CCNT1CDK1CDK4
SCHEMBL2262093 0.89 KCNH2 (0.51) KCNH2CYP2C9CDK1CDK2CYP3A4
SCHEMBL2264155 0.87 KCNH2 (0.53) KCNH2CYP2C9CCNKCDK12CYP2C19
SCHEMBL2260009 0.86 KCNH2 (0.39) KCNH2CYP2C9SMOCCNT1CDK1
SCHEMBL2263677 0.86 KCNH2 (0.45) KCNH2CYP2C9CDK1CDK4CCND1
SCHEMBL2259839 0.85 KCNH2 (0.47) KCNH2CYP2C9CCNKCDK12PSEN1
SCHEMBL2265614 0.85 KCNH2 (0.52) KCNH2CYP2C9SMOCCNT1CDK1
SCHEMBL2262338 0.85 KCNH2 (0.47) KCNH2CYP2C9CYP3A4CYP2D6CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2089384-B1 2-(PIPERIDIN-4-YL)-4-PHENOXY-OR PHENYLAMINO-PYRIMIDINE DERIVATIVES AS NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS HOFFMANN LA ROCHE (CH) 2015-08-05 EP claimed
US-7998969-B2 enzyme inhibitors such as 4-[2-(1-Benzyl-piperidin-4-ylamino)-pyrimidin-4-yloxy]-3,5-dimethyl-benzonitrile, used in combination with other viricides, for preventing and treatment of viral infections such as HIV, AIDS and AIDS related diseases ROCHE PALO ALTO LLC (US) 2011-08-16 US claimed
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors ROCHE PALO ALTO LLC 2008-06-19 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146595-A1 Non-nucleoside reverse transcriptase inhibitors NQO2, SAMHD1, POLR2A KCNH2 4033/4885CYP2C9 1382/4885SMO 4666/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.